|
 The patent covers BrainStorm's stem cells induced to
secrete elevated levels of neurotrophic factors for the treatment of
neurodegenerative diseases.
Pending approval from the U.S. Food & Drug Administration, the
company is preparing for its upcoming mid-stage Phase II trial in
the United States with its NurOwn adult stem cell therapy.
BrainStorm is developing NurOwn for the treatment of amyotrophic
lateral sclerosis (ALS), also known as Lou Gehrig's Disease, a
progressive neurodegenerative disease that affects nerve cells in
the brain and spinal cord.
Separately, the company said it has signed a definitive agreement
with Massachusetts General Hospital in Boston to conduct a Phase II
clinical trial of NurOwn in ALS, pending FDA approval. The other two
clinical sites slated for the trial are the University of
Massachusetts Memorial Hospital and Mayo Clinic.
"The recent bill introduced to the U.S. Senate to support
regenerative medicine research is yet another indication of the
increasing recognition that stem cells hold the promise for curing
life-threatening and debilitating conditions like ALS," said Chaim
Lebovits, BrainStorm's president.
[to top of second column] |
"We are very encouraged by the bill's proposal to appoint a
council that would develop and maintain a national strategy for the
promotion of regenerative medicine research and development."
(Reporting by Tova Cohen)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
